
Pharmacally
COPD
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in COPD
Clinical TrialsAer Therapeutics Reports Phase 2a Failure for Fexlamose in COPDAer Therapeutics’ investigational therapy fexlamose failed to meet its Phase 2a efficacy endpoints in moderate-to-severe COPD, showing no improvement in pulmonary function or overall mucus-plug burden after 28…Fact-Checked
Health TidingsExpedition Raises $115M to Advance EXPD-101 Phase 2 COPD TrialExpedition Therapeutics has secured $115 million in an oversubscribed Series B financing to advance EXPD-101, its investigational oral DPP1 inhibitor for COPD, into Phase 2 clinical development.Fact-Checked
Mergers & AcquisitionsSino Biopharmaceutical Licenses COPD Candidate TQC3721 to AstraZeneca in Up to $2.1 Billion Respiratory DealSino Biopharmaceutical has entered one of 2026’s largest respiratory licensing agreements, granting AstraZeneca exclusive global rights to TQC3721, its late‑stage inhaled dual PDE3/4 inhibitor for COPD.Fact-Checked
Clinical TrialsAstraZeneca Reports Positive Phase III Data for Tozorakimab in COPDTozorakimab significantly reduced exacerbations in chronic obstructive pulmonary disease (COPD) patients across broad populations in Phase III OBERON and TITANIA trials, marking a potential first-in-class IL-33 targeted therapy.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.